单次注射尿激酶对IgA肾病患者纤溶活性的影响。

Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.

作者信息

Tomino Y, Miura M, Suga T, Yagame M, Endoh M, Nomoto Y, Sakai H, Itoh K, Ikeda N

出版信息

Tokai J Exp Clin Med. 1984 Mar;9(1):43-7.

Abstract

A study on the clinical effects of urokinase in patients with IgA nephropathy is described. Three different methods of administration, including single, continuous, and mixed administration, were employed in this study. Measurements of plasminogen, plasmin and alpha 2-plasmin inhibitor levels in plasma were performed during the course of urokinase administration in patients with IgA nephropathy and chronic proliferative glomerulonephritis. Measurements of alpha 1-anti-trypsin and alpha 2-macroglobulin levels were also performed in these patients. Urinalysis was performed both before and after administration of urokinase. It was demonstrated that a single shot of urokinase induced a significant fibrinolytic activity in patients with IgA nephropathy, and that a single shot of urokinase was effective in improving proteinuria and/or hematuria in patients with IgA nephropathy. It is concluded that a single shot of urokinase may be useful for treatment of patients with IgA nephropathy.

摘要

本文描述了一项关于尿激酶对IgA肾病患者临床疗效的研究。本研究采用了三种不同的给药方法，包括单次给药、连续给药和混合给药。在IgA肾病和慢性增殖性肾小球肾炎患者使用尿激酶的过程中，对血浆中的纤溶酶原、纤溶酶和α2-纤溶酶抑制剂水平进行了测量。还对这些患者的α1-抗胰蛋白酶和α2-巨球蛋白水平进行了测量。在尿激酶给药前后均进行了尿液分析。结果表明，单次注射尿激酶可在IgA肾病患者中诱导显著的纤溶活性，且单次注射尿激酶对改善IgA肾病患者的蛋白尿和/或血尿有效。得出的结论是，单次注射尿激酶可能对IgA肾病患者的治疗有用。